



**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



PCT/680

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




P. Mahoney

Signed

Dated 5 August 2004

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)

The
Patent
Office

16JUL03 E823076-1 D02973
P01/7700 0.00-0316629.5

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference

P103121GB

2. Patent application number

(The Patent Office will fill in this part)

0316629.5

16 JUL 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

The University of York
Healington
York
YO1 5DD
GB

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
country/state of its incorporation

7511405002

4. Title of the invention

Transgenic Cell

5. Name of your agent (if you have one)

Harrison Goddard Foote

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

31 St Saviourgate
YORK
YO1 8NQ

Patents ADP number (if you know it)

07014237002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if)

- a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

yes

Patents Form 1/77

0074675 16 JUL 03 05:31

Patents Form 1/77

8. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 28 /

Claim(s) 4 /

Abstract 1 /

Drawing(s) 13 /

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 8/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

16 July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Rob Docherty

01904 732120

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 28 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500605.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

DUPLICATE

Transgenic Cells

The invention relates to transgenic cells comprising nucleic acid molecules which comprise nucleic acid sequences which encode enzymes involved in the biosynthesis of n-3 fatty acids.

DHA, an example of a n-3 fatty acid can be obtained directly from the diet or derived from metabolism of dietary linoleic and α -linolenic acid. To obtain sufficient amounts of this fatty acid humans have to eat foods rich in DHA. Currently the principle dietary source of DHA is fish or fish oil. However, this has many inherent problems; fish accumulate pollutants, the extracted oil has an unpleasant odour, there is a difficulty in controlling the proportion of specific desirable fatty acids from this source and since fish are a declining resource the market demand for DHA is not being met. Also, vegetarians do not have an obvious alternative food source to fish and therefore either do without DHA or have to take pure supplements.

Long chain polyunsaturated fatty acids (LPUFAs) are derived from the essential fatty acids (EFA) linoleic acid (18:2n-6) and α -linolenic acid (18:3n-3), the parent compounds of the so-called omega-3 and omega-6 EFA families by an alternating series of desaturation and elongation reactions (Haag, 2001), see Figure 4. The major metabolite product of the n-6 pathway in mammals is arachidonic acid (AA) (20:4n-6), whilst the major end products of the n-3 pathway are eicosapentaenoic acid (EPA) (20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). The biosynthesis of 18:3n-3 from 18:4n-3 involves the action of a Δ 6 desaturase (Horrobin DF, 1992). This is followed by an elongation reaction to 20:4n-3 (Sprecher *et al.*, 1995) and a Δ 5 desaturation to 20:5n-3 (Sprecher *et al.*, 1995). The conventional view is that there is then a further elongation step converting 20:5n-3 to 22:5n-3, which is then followed by a final desaturation step involving the activity of a Δ 4 desaturase to produce DHA (22:6n-3).

During evolution humans have consumed a diet containing approximately equal ratio of n-3 and n-6 essential fatty acids (1-2:1), but the last 100-150 years has seen a growing trend in Western diets towards the consumption of more n-6 fatty acids, resulting in an alteration of the ratio to 30:1 (Simonpolous, 1999). Whilst an
5 increased intake of n-6 fatty acids is characterised by cardiovascular problems such as increased blood viscosity, vasospasm and vasoconstriction, the n-3 fatty acids are associated with health promoting properties. For example n-3 fatty acids have been described as anti-inflammatory, antithrombotic, antiarrhythmic, hypolipidemic and vasodilatory (Simonpolous, 1999). As such the role of DHA in the prevention and/or
10 treatment of diseases such as coronary heart disease, hypertension, type II diabetes, ocular diseases, arthritis, cystic fibrosis and schizophrenia and has been the focus of a great deal of medical research.

The effect of n-3 polyunsaturated fatty acids in the cardiovascular diseases has shown
15 that dietary intake of DHA can lower the risk of myocardial infarction, hypertension and complications associated with cardiac surgery. A number of population studies have correlated the dietary intake of DHA with cardiovascular risk factors. For instance, a study of a population of Inuits in Canada (426 subjects aged 18-74 yr), who traditionally consume large amounts of marine foods rich in n-3 fatty acids,
20 showed that n-3 fatty acids, such as DHA were positively associated with HDL-cholesterol concentrations and inversely associated with triacylglycerol concentrations and the ratio of total to HDL cholesterol (Dewailly *et al.*, 2001). It was concluded that the high dietary intake of n-3 fatty acids in the Inuit diet was probably responsible for the low mortality rate from ischemic heart disease in this
25 population.

Essential fatty acids are structural components of all tissues and are indispensable for cell membrane synthesis. The brain, retina and other neural tissues have been found to be particularly rich in DHA, where it is involved in neural development and
30 maturation of sensory systems (Uauy *et al.*, 2000). A large body of research comparing infants fed with breast milk compared to formula milk, which is deficient in DHA and other omega 3- fatty acids, has concluded that the presence of DHA is

critical during the development of the newborn (Horrocks *et al.*, 1999). DHA forms 25% of the fatty acid complement of the glycosphingolipids of the brain and is an important component of the rods of the retina, and therefore a deficiency in DHA during infant development has been associated with a reduction in cognitive function and visual acuity. Furthermore, deficiencies in DHA have been associated with foetal alcohol syndrome, attention deficit hyperactivity disorder, cystic fibrosis, phenylketonuria and adrenoleukodystrophy.

To meet this increased demand for n-3 fatty acids such as DHA a number of approaches have been attempted. Methods to enhance the DHA content of meat by manipulating animal feed have been met with little success. The cultivation of marine micro-organisms such as the *Cryptocodinium cohnii* and *Schizochytrium* sp, which are rich sources of DHA has also met with some limited success as the cultivation of algae is technically demanding and costly (Ashford *et al.*, 2000).

There has been limited research focused on the identification of genes involved in the biosynthesis of n-3 fatty acids in algae. In one report the identification of a cDNA encoding a novel C18- Δ^9 polyunsaturated fatty acid-specific elongating activity from the docosahexaenoic acid (DHA)-producing microalga, *Isochrysis galbana* was described (Qi *et al.*, 2002). This 30 kDa elongase, designated IgASE1, shares only limited homology to animal and fungal proteins with elongating activity. When IgASE1 was expressed in the yeast *Saccharomyces cerevisiae*, it was shown to specifically elongate the C18- Δ^9 polyunsaturated fatty acids, linoleic acid (C18:2n-6, $\Delta^{9,12}$ and alpha-linolenic acid (C18:3, $\Delta^{9,12,15}$), to eicosadienoic acid (C20:2, $\Delta^{11,14}$) and eicosatrienoic acid (C20:3 $\Delta^{11,14,17}$), respectively. It was concluded that a major route for eicosapentaenoic acid (C20:5 $\Delta^{5,8,11,14,17}$) and docosahexaenoic acid (C22:6 $\Delta^{4,7,10,13,16,19}$) syntheses in *I. galbana* may involve a Δ^8 desaturation pathway.

$\Delta 6$ and $\Delta 5$ desaturases are microsomal enzymes that are thought to be a component of a three-enzyme system that includes NADH-cytochrome b_5 reductase, cytochrome b_5 , and the respective desaturase (Sprecher, 1981).

- 5 A number of $\Delta 6$ and $\Delta 5$ desaturases have been identified. In plants such as the herb, borage (*Borago officinalis*), the $\Delta 6$ desaturase has been identified (Sayanova *et al.*, 1997). $\Delta 6$ and $\Delta 5$ desaturases have been identified in humans (Hyekyung *et al.*, 1999 and Cho *et al.*, 1999, respectively), in animals such as the nematode, *Caenorhabditis elegans* (Michaelson *et al.*, 1998 and Napier *et al.*, 1998) and in eukaryotic
- 10 microorganisms such as the fungus *Mortierella alpina* (Huang *et al.*, 1999 and Knutzon *et al.*, 1998). In the human, $\Delta 6$ and $\Delta 5$ desaturase activities have been found in skeletal muscle, lung, placenta, kidney and pancreas, but are expressed at the highest levels in the liver, brain and heart (Hyekyung *et al.*, 1999). In all these tissues however, $\Delta 6$ desaturase activity was found to be higher than that of $\Delta 5$ desaturase.
- 15 The genes for both of the enzymes reside on chromosome 11, in a reverse orientation, being separated by <11,000 base pairs (Hyekyung *et al.*, 1999). A $\Delta 4$ desaturase that can introduce a double bond at position 4 of 22:5 n-3 and 22:4 n-6 resulting in the production of DHA and docosapentanoic acid has been identified in the marine fungi *Thraustochytrium* sp (Qiu *et al.*, 2001).

20

- Cellular storage of fatty acids in triacylglycerol requires that the fatty acids are first activated to their acyl-CoA esters through the action of acyl-CoA synthetase enzyme. Acyl-CoA's are produced by acyl-CoA synthetase from fatty acid, ATP and Coenzyme A. Acyl-CoA synthetases can exhibit substrate specificity for different
- 25 chain length or different degrees of saturation of the fatty acid. For example an arachidonate (20:4 n-6)-preferring acyl-CoA synthetase has been identified in rat (Kang *et al.*, 1997). This enzyme has a high affinity for arachidonate and EPA and low affinity for palmitate. Several isoforms of acyl-CoA synthetases have also been identified in *Arabidopsis* (Schmurr *et al.*, 2000).

30

Acyl CoA:diacylglycerol acyltransferase (DGAT) catalyses the final enzymatic step in the production of triacylglycerols in plants, fungi and mammals. The enzyme is responsible for transferring an acyl group from acyl-CoA to the *sn*-3 position of 1,2-diacylglycerol (DAG) to form triacylglycerol (TAG). The first cloning of a DGAT gene was from mouse (Cases *et al.*, 1998). An *Arabidopsis* homologue of the mouse DGAT gene was subsequently reported and found to be present as a single copy gene (Hobbs *et al.*, 1999). Jako *et al.*, (2001) showed that the *Arabidopsis Tag1* mutant which is disrupted in the DGAT gene and has a fatty acid and reduced oil phenotype can be complemented by expression of the DGAT cDNA. Jako *et al.*, (2001) also showed that seed-specific over-expression of the DGAT cDNA in wild-type *Arabidopsis* enhances oil deposition and average seed weight thus confirming the important role of DGAT in regulating the quantity of seed triacylglycerols and the sink size in developing seeds. Protein purification based studies on the oleaginous fungus *Mortierella ramanniana* resulted in the identification of a second class of proteins involved in TAG production that are encoded by the *DGAT2* gene family that are unrelated to the previously identified *DGAT1* gene family (Lardizabal *et al.*, 2001). A human homologue of the *Mortierella ramanniana* *DGAT2* gene has been also been identified (Cases *et al.*, 2001). Substrate specificities of the different families have yet to be determined.

Whilst higher plants do not typically biosynthesise LPUFAs such as DHA, they are an attractive target for genetic manipulation, particularly the low cost production of DHA in the vegetable oil of a crop such as oilseed rape. There have been no reports of higher plants that biosynthesise DHA, a number of attempts to introduce algal genes in order to manipulate the biosynthetic capacity of oil seed plants that produce LPUFAs have been reported. These have included the introduction of desaturases into transgenic plants to increase the production of DHA, EPA and also stearidonic acid (18:4n-3).

We herein disclose nucleic acid molecules which encode enzymes involved in n-3 fatty acid metabolism and the manipulation of these sequences and the biochemical

pathways which comprise enzymes encoded by these sequences, to provide an alternative dietary source of n-3 fatty acids and, in particular, DHA. The sequences encode n-3 fatty acid elongase, desaturase, acyl CoA synthetase and diacylglycerol acyltransferase activities.

5

According to an aspect of the invention there is provided a transgenic cell comprising a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

- 10 (i) a DNA molecule consisting of a DNA sequence as represented in Figures 1a, 1b or 1c;
- (ii) a DNA molecule which hybridises to the sequences identified in (i) above and which encode a polypeptide which has fatty acid elongase activity; and
- 15 (iii) DNA molecules consisting of DNA sequences that are degenerate as a result of the genetic code to the DNA sequence defined in (i) and (ii)

In a preferred embodiment of the invention said nucleic acid molecule anneals under stringent hybridisation conditions to the sequences described in (i), (ii) and (iii) above.

20

Stringent hybridisation/washing conditions are well known in the art. For example, nucleic acid hybrids that are stable after washing in 0.1xSSC, 0.1% SDS at 60°C. It is well known in the art that optimal hybridisation conditions can be calculated if the sequence of the nucleic acid is known. Typically, hybridisation conditions uses 4 – 6
25 x SSPE (20x SSPE contains 175.3g NaCl, 88.2g NaH₂PO₄ H₂O and 7.4g EDTA dissolved to 1 litre and the pH adjusted to 7.4); 5-10x Denhardt's solution (50x Denhardt's solution contains 5g Ficoll (Type 400, Pharmacia), 5g polyvinylpyrrolidone and 5g bovine serum albumen); 100µg-1.0mg/ml sonicated salmon/herring DNA; 0.1-1.0% sodium dodecyl sulphate; optionally 40-60%
30 deionised formamide. Hybridisation temperature will vary depending on the GC content of the nucleic acid target sequence but will typically be between 42°- 65° C.

In a preferred embodiment of the invention said nucleic acid molecules are isolated from an algal species.

Preferably said algal species is selected from the group consisting of: *Amphidinium carterae*, *Amphiphora hyalina*, *Amphiphora* sp., *Chaetoceros gracilis*, *Coscinodiscus* sp., *Cryptocodinium cohnii*, *Cryptomonas* sp., *Cylindrotheca fusiformis*, *Haslea ostrearia*, *Isochrysis galbana*, *Nannochloropsis oculata*, *Navicula* sp., *Nitzschia closterium*, *Pavlova lutheri*, *Phaeodactylum tricornutum*, *Prorocentrum minimum*, *Rhizosolenia setigera*, *Skeletonema costatum*, *Skeletonema* sp., *Tetraselmis tetraele*, *Thalassiosira nitzschoides*, *Thalassiosira heterophormis*, *Thalassiosira pseudomana*, *Thalassiosira stellaris*.

In a further preferred embodiment of the invention said polypeptide is a variant polypeptide and comprises the amino acid sequence represented in Figure 2a, 2b, or 2c which sequence has been modified by deletion, addition or substitution of at least one amino acid residue wherein said modification enhances the enzyme activity of said polypeptide.

A variant polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions, truncations which may be present in any combination. Among preferred variants are those that vary from a reference polypeptide by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid by another amino acid of like characteristics. The following non-limiting list of amino acids are considered conservative replacements (similar): a) alanine, serine, and threonine; b) glutamic acid and aspartic acid; c) asparagine and glutamine d) arginine and lysine; e) isoleucine, leucine, methionine and valine and f) phenylalanine, tyrosine and tryptophan. Most highly preferred are variants which retain or enhance the same biological function and activity as the reference polypeptide from which it varies.

A functionally equivalent polypeptide(s) according to the invention is a variant wherein one in which one or more amino acid residues are substituted with conserved or non-conserved amino acid residues, or one in which one or more amino acid residues includes a substituent group. Conservative substitutions are the
5 replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among aromatic residues Phe and Tyr.

In addition, the invention features polypeptide sequences having at least 75% identity
10 with the polypeptide sequences as herein disclosed, or fragments and functionally equivalent polypeptides thereof. In one embodiment, the polypeptides have at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, still more preferably at least 97% identity, and most preferably at least 99% identity with the amino acid sequences illustrated herein.

15

Ideally said modified polypeptide has enhanced fatty acid elongase activity

In a further preferred embodiment of the invention said polypeptide comprises the amino acid sequence represented in Figures 2a, 2b or 2c. Preferably said polypeptide
20 consists of the amino acid sequence represented in Figures 2a, 2b or 2c.

According to a further aspect of the invention there is provided a vector including at least one nucleic acid molecule wherein said nucleic acid molecule is selected from the group consisting of:

25

- i) a DNA molecule consisting of a DNA sequence as represented in Figures 1a, 1b or 1c;
- ii) a DNA molecule which hybridises to the sequences identified in (i) above and which encode a polypeptide which has fatty acid elongase
30 activity; and

iii) DNA molecules consisting of DNA sequences that are degenerate as a result of the genetic code to the DNA sequence defined in (i) and (ii)

5 A vector including nucleic acid (s) according to the invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome for stable transfection.

10 Preferably the nucleic acid in the vector is operably linked to an appropriate promoter or other regulatory elements for transcription in a host cell such as a prokaryotic, (e.g. bacterial), or eukaryotic (e.g. fungal, plant, mammalian or insect cell). The vector may be a bi-functional expression vector which functions in multiple hosts. In the example of nucleic acids encoding polypeptides according to the invention this may contain its native promoter or other regulatory elements and in the case of cDNA this
15 may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell.

By "promoter" is meant a nucleotide sequence upstream from the transcriptional initiation site and which contains all the regulatory regions required for transcription.
20 Suitable promoters include constitutive, tissue-specific, inducible, developmental or other promoters for expression in plant cells comprised in plants depending on design. Such promoters include viral, fungal, bacterial, animal and plant-derived promoters capable of functioning in plant cells.

25 Constitutive promoters include, for example CaMV 35S promoter (Odell *et al* (1985) Nature 313, 9810-812); rice actin (McElroy *et al* (1990) Plant Cell 2: 163-171); ubiquitin (Christian *et al* . (1989) Plant Mol. Biol. 18 (675-689); pEMU (Last *et al* (1991) Theor Appl. Genet. 81: 581-588); MAS (Velten *et al* (1984) EMBO J. 3. 2723-2730); ALS promoter (U.S. Application Serial No. 08/409,297), and the like.
30 Other constitutive promoters include those in U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680, 5,268,463; and 5,608,142.

Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon the objective, the promoter may be a chemical-inducible promoter, where application of the chemical induces gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-1a promoter, which is activated by salicylic acid. Other chemical-regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena *et al* (1991) *Proc. Natl. Acad. Sci. USA* 88: 10421-10425 and McNellie *et al.* (1998) *Plant J.* 14(2): 247-257) and tetracycline-inducible and tetracycline-repressible promoters (see, for example, Gatz *et al.* (1991) *Mol. Gen. Genet.* 227: 229-237, and US Patent Nos. 5,814,618 and 5,789,156, herein incorporated by reference.

Where enhanced expression in particular tissues is desired, tissue-specific promoters can be utilised. Tissue-specific promoters include those described by Yamamoto *et al.* (1997) *Plant J.* 12(2): 255-265; Kawamata *et al* (1997) *Plant Cell Physiol.* 38(7): 792-803; Hansen *et al* (1997) *Mol. Gen. Genet.* 254(3): 337-343; Russell *et al.* (1997) *Transgenic Res.* 6(2): 157-168; Rinehart *et al* (1996) *Plant Physiol.* 112(3): 1331-1341; Van Camp *et al* (1996) *Plant Physiol.* 112(2): 525-535; Canevaschi *et al* (1996) *Plant Physiol.* 112(2): 513-524; Yamamoto *et al* (1994) *Plant Cell Physiol.* 35(5): 773-778; Lam (1994) *Results Probl. Cell Differ.* 20: 181-196; Orozco *et al* (1993) *Plant Mol. Biol.* 23(6): 1129-1138; Mutsaers *et al* (1993) *Proc. Natl. Acad. Sci. USA* 90(20): 9586-9590; and Guevara-Garcia *et al* (1993) *Plant J.* 4(3): 495-50.

In a preferred embodiment of the invention said tissue specific promoter is a promoter which is active during the accumulation of oil in developing oil seeds, see Broun *et al.* (1998) Plant J. 13(2): 201-210.

- 5 "Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.
- 10 In a preferred embodiment the promoter is an inducible promoter or a developmentally regulated promoter.
- Particular vectors are nucleic acid constructs which operate as plant vectors. Specific procedures and vectors previously used with wide success upon plants are described
- 15 by Guerinneau and Mullineaux (1993) (Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148. Suitable vectors may include plant viral-derived vectors (see e.g. EP-A-194809).
- 20 Vectors may also include selectable genetic marker such as those that confer selectable phenotypes such as resistance to herbicides (e.g. kanamycin, hygromycin, phosphinotricin, chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate).
- 25 Alternatively, or in addition, said vectors are vectors suitable for mammalian cell transfection or yeast cell transfection. In the latter example multi-copy vectors such as 2 μ episomal vectors are preferred. Alternatively yeast CEN vectors and integrating vectors such as YIP vectors are suitable for transformation of yeast species such as *Saccharomyces cerevisiae* and *Pichia* spp.
- 30

It will be apparent to one skilled in the art that a vector according to the invention may include nucleic acid molecules encoding different enzyme activities to facilitate

the delivery of different enzyme activities to a transfected or transformed cell to reconstitute enzymic pathways.

- In a preferred embodiment of the invention said cell is transformed with nucleic acid molecules selected from the group consisting of nucleic acid sequences encoding elongase and desaturase and/or acyl-CoA synthetase and/or diacylglycerol acyltransferase activities to provide a cell in which at least part of a 3-n fatty acid biosynthetic pathway is reconstituted.
- 10 In a further preferred embodiment of the invention said cell is transfected with a nucleic acid molecules selected from the group comprising nucleic acid sequences selected from the group consisting of:
- i) a DNA molecule consisting of the DNA sequence as represented in Figures 1a, 1b or 1c;
 - 15 ii) DNA molecules which hybridise to the sequences identified in (i) above and which encode a polypeptide which has fatty acid elongase activity; and
 - iii) DNA molecules comprising DNA sequences that are degenerate as a result of the genetic code to the DNA sequence defined in (i) and (ii); combined with at least one of the nucleic acid molecules selected from the group consisting of,
 - 20 iv) DNA molecules consisting of DNA sequences as represented in Figures 3a, 4a, 5a or 6a;
 - v) DNA molecules which hybridise to the sequences identified in (iv) above and which have desaturase, acyl-CoA synthetase or diacylglycerol acyltransferase activity;
 - 25 vi) DNA molecules comprising DNA sequences that are degenerate as a result of the genetic code to the DNA sequence defined in (iv) and (v) above.

30

In a preferred embodiment of the invention said cell is selected from the group consisting of: mammalian cells (e.g. Chinese Hamster Ovary cells); yeast cells (e.g. *Saccharomyces* spp, *Pichia* spp); algal cells (e.g. *Phaeodactylum tricornutum*, *Chlamydomonas reinhardtii*); plant cells.

5

In a preferred embodiment of the invention said cell is a plant cell.

According to a further aspect of the invention there is provided a plant comprising a cell according to the invention.

10

In a preferred embodiment of the invention said plant is selected from: corn (*Zea mays*), canola (*Brassica napus*, *Brassica rapa* ssp.), flax (*Linum usitatissimum*), alfalfa (*Medicago sativa*), rice (*Oryza sativa*), rye (*Secale cereale*), sorghum (*Sorghum bicolor*, *Sorghum vulgare*), sunflower (*Helianthus annuus*), wheat (*Triticum aestivum*),

15 soybean (*Glycine max*), tobacco (*Nicotiana tabacum*), potato (*Solanum tuberosum*), peanuts (*Arachis hypogaea*), cotton (*Gossypium hirsutum*), sweet potato (*Ipomoea batatas*), cassava (*Manihot esculenta*), coffee (*Coffea* spp.), coconut (*Cocos nucifera*), pineapple (*Ananas comosus*), citrus tree (*Citrus* spp.) cocoa (*Theobroma cacao*), tea (*Camellia sinensis*), banana (*Musa* spp.), avocado (*Persea americana*), fig (*Ficus carica*),
20 guava (*Psidium guajava*), mango (*Mangifera indica*), olive (*Olea europaea*), papaya (*Carica papaya*), cashew (*Anacardium occidentale*), macadamia (*Macadamia integrifolia*), almond (*Prunus amygdalus*), sugar beets (*Beta vulgaris*), oats, barley, vegetables and ornamentals.

25 Preferably, plants of the present invention are crop plants (for example, cereals and pulses, maize, wheat, potatoes, tapioca, rice, sorghum, millet, cassava, barley, pea), and other root, tuber or seed crops. Important seed crops are oil-seed rape, sugar beet, maize, sunflower, soybean, sorghum, and flax (linseed). Horticultural plants to which the present invention may be applied may include lettuce, endive, and
30 vegetable brassicas including cabbage, broccoli, and cauliflower. The present invention may be applied in tobacco, cucurbits, carrot, strawberry, sunflower, tomato, pepper.

Grain plants that provide seeds of interest include oil-seed plants and leguminous plants. Seeds of interest include grain seeds, such as corn, wheat, barley, rice, sorghum, rye, etc. Oil-seed plants include cotton, soybean, safflower, sunflower, 5 Brassica, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans and peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea, mungbean, lima bean, fava bean, lentils, chickpea, etc.

10 It will be apparent that transgenic plants adapted for the production of n-3 fatty acids, in particular DHA, can either be eaten directly or used as a source for the extraction of essential fatty acid, of which DHA would be a constituent.

According to a yet further aspect of the invention there is provided a seed comprising a cell according to the invention.

15

In a further preferred embodiment of the invention said cell is a yeast cell, preferably of the genus *Saccharomyces* spp, preferably Brewer's yeast *Saccharomyces cerevisias*.

20 The genus *Saccharomyces* spp is used in both brewing of beer and wine making and also as an agent in baking, particularly bread. Yeast is a major constituent of vegetable extracts of which Marmite[™] is a typical example. Yeast is also used as an additive in animal feed. It will be apparent that genetically engineered yeast strains can be provided which are adapted to synthesise n-3 fatty acids. These yeast strains 25 can then be used in food stuffs and in wine and beer making to provide products which have enhanced n-3 fatty acid content and in particular DHA content.

According to a further aspect of the invention there is provided a foodstuff product comprising a yeast cell according to the invention.

30

In a preferred embodiment of the invention said foodstuff product is selected from the group consisting of: wine; beer; bread, baking products (e.g. bread, cake); vegetable extracts.

- 5 In a further preferred embodiment of the invention said wine or beer is non-alcoholic.

According to a further aspect of the invention there is provided a fermentation process comprising a yeast cell according to the invention.

10

In a preferred embodiment of the invention said fermentation process comprises the steps of:

- 15 i) providing a vessel containing a yeast cell according to the invention and constituents required for fermentation and fatty acid biosynthesis; and
ii) providing conditions conducive to the fermentation of the liquid composition contained in said vessel.

20 According to a yet further aspect of the invention there is provided an animal feed product comprising a cell according to the invention.

In a preferred embodiment of the invention said cell is a plant cell or yeast cell.

25 According to a further aspect of the invention there is provided a method of modulating the level of n-3 fatty acid, in particular DHA, or variants thereof, in a plant cell comprising:

- 30 i) providing a plant cell according to the invention;
ii) regenerating the plant cell into a plant; and
iii) monitoring n-3 fatty acid production by said plant.

According to a further aspect of the invention there is provided a method for the production and optionally the extraction of n-3 fatty acids, in particular DHA, comprising:

- 5 i) providing a cell according to the invention;
 ii) providing conditions conducive to the growth of said cell; and
 iii) extracting n-3 fatty acids, or variants thereof, from said cell.

10 According to a yet further aspect of the invention there is provided a method for the production and optionally the extraction of n-3 fatty acid, particularly DHA, comprising:

- i) providing a plant cell according to the invention;
 ii) regenerating said cell into a plant; and
15 iii) extracting n-3 fatty acids, or variants thereof from said plant.

According to a further aspect of the invention there is provided n-3 fatty acids, particularly DHA, or variants thereof, obtainable by the method(s) according to the invention.

20

In a preferred embodiment of the invention said n-3 fatty acid, or variant thereof, is for use as a pharmaceutical.

25 In a further preferred embodiment of the invention said n-3 fatty acid, or variant thereof, is for use in the manufacture of a medicament for use in the treatment of conditions which would benefit from administration of n-3 fatty acids, or variant thereof.

30 In a preferred embodiment of the invention said condition is selected from the group consisting of: cardiac arrhythmia's; rheumatoid arthritis; Crohn's disease; schizophrenia; cancer; foetal alcohol syndrome; attention deficient hyperactivity

disorder; cystic fibrosis; phenylketonuria; unipolar depression; aggressive hostility; adrenoleukodystrophy; coronary heart disease, hypertension, type II diabetes, ocular diseases.

- 5 According to a further aspect of the invention there is provided a non-human transgenic animal comprising at least one nucleic acid molecule according to the invention.

- 10 According to a yet further aspect of the invention there is provided a reaction vessel comprising at least one polypeptide according to the invention, fatty acid substrates and co-factors characterised in that said vessel is adapted for the conversion of said fatty acids substrates to n-3 fatty acids, in particular docosahexaenoic acid.

- 15 In a preferred embodiment of the invention said vessel comprises polypeptides having elongase, desaturase, acyl-CoA synthetase and diacylglycerol acyltransferase activities to provide a vessel in which at least part of a 3-n fatty acid biosynthetic pathway is reconstituted.

- 20 In a further preferred embodiment of the invention said polypeptides are those protein molecules disclosed herein. In particular, protein molecules which comprise the sequences as represented by Figures 2a, 2b, 2c, 3b, 4b, 5b or 6b.

- In a preferred embodiment of the invention said at least one polypeptide is expressed by a cell according to the invention.

25

In a preferred embodiment of the invention said polypeptide(s) is/are soluble. Alternatively said polypeptide(s) is/are immobilised.

30

In a further preferred embodiment of the invention said vessel is a bioreactor.

It will be apparent to one skilled in the art that a polypeptide according to the invention has utility with respect to the *in vivo* biosynthesis of n-3 fatty acids through transformation or transfection of nucleic acids encoding said polypeptide(s) into suitable host cells. Fatty acids can then either be extracted from said cells or foods comprising said cells can be eaten. Cells expressing said polypeptide (s) can also be incubated under suitable growth conditions to facilitate the synthesis of fatty acids. Alternatively, said polypeptide (s) can either be purified from an algal cell culture or manufactured recombinantly and used in a bioreactor to synthesise fatty acids *in vitro*. It will also be apparent that the invention involves, *inter alia*, the reconstitution of at least part of an algal n-3 fatty acid biosynthetic pathway which, either in a cell or *in vitro*, provides for a source of n-3 fatty acids which is an alternative to either the exploitation of algae in bioreactors or the consumption of fish.

An embodiment of the invention will now be described by example only and with reference to the following figures:

Figure 1a represents the nucleic acid sequence of a nucleic acid molecule comprising a fatty acid elongase TpELO2.1; Figure 1b the nucleic acid sequence of the fatty acid elongase TpELO2.2; Figure 1c the nucleic acid sequence of the fatty acid elongase TpELO2.3;

Figure 2a represents the amino acid sequence of TpELO2.1; Figure 2b represents the amino acid sequence of TpELO2.2; and ; Figure 2b represents the amino acid sequence of TpELO2.3;

Figure 3a represents the nucleic acid sequence of *PIDES1*; Figure 3b represents the amino acid sequence of *PIDES1*;

Figure 4a represents the nucleic acid sequence of a nucleic acid molecule comprising fatty acid desaturase, *PIDES2*; Figure 4b the amino acid sequence comprising *PIDES2*;

Figure 5a represents the nucleic acid sequence of a nucleic acid molecule comprising acyl-CoA synthetase, *PLACSI*; Figure 5b the amino acid sequence comprising *PLACSI*;

5

Figure 6a the full length sequence of a nucleic acid molecule encoding *PIDGAT2-1*; Figure 6b the full length amino acid sequence of *PIDGAT2-1* polypeptide; and

Figure 7a is the nucleic acid sequence of *PIELO1*; Figure 7b amino acid sequence of *PIELO 1*; Figure 7c is the nucleic acid sequence of *PIELO 2*; Figure 7d is the amino acid sequence of *PIELO 2*.

MATERIALS AND METHODS

15

Cultivation of *Pavlova lutheri*

Pavlova lutheri (CCAP 931/1) was obtained from the Culture Collection of Algae and Protozoa (Dunstaffnage Marine Lab., Oban, PA34 4AD, Scotland, U.K.).

20

The growth medium used in all experiments was enriched artificial seawater medium (EASW), made up in 20 l batches as described by Harrison et al. (1980), and modified by Thompson et al. (1991). The medium was further modified by increasing the macronutrient concentrations of NaNO_3 and $\text{Na}_2\text{SiO}_3 \cdot 9\text{H}_2\text{O}$ to 1 mM, and NaH_2PO_4 to 200 μM . The silicate was dissolved separately in deionized distilled water and the pH adjusted to approximately 8.0 with 50% HCl before it was added to the medium. This medium was buffered to pH 8.0 by adding 20 mM N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] (HEPES) and 20 mM NaOH. The freshly prepared medium was filtered through a 0.22 μM Millipore™ GS membrane filter into a 20 l sterile propylene reservoir. It was then dispatched by 0.5 l in 1 l conical glass flasks and sterilized by autoclaving (30 min, 120°C). The batch

30

cultures were grown at 15°C with 50 $\mu\text{E m}^{-2} \text{s}^{-1}$ constant illumination, and aeration provided by shaking the flasks at 150 rpm.

Cell density was monitored by counting cells with a haemocytometer. Since the
5 *Pavlova lutheri* cells are motile, they were first incubated in sodium azide 20 mM to immobilise before counting.

The nitrate concentration was determined periodically during the culture time by measuring the change of the medium absorbance at 220 nm, according to the method
10 described by Collos et al. (1999).

Isolation of total and poly(A)⁺ RNA from *P. lutheri*

The algal culture was harvested by centrifugation at 4,500 rpm for 15 min. The cell
15 pellet was suspended in 1 volume of extraction buffer (25 mM Tris-HCl pH 8.0, 25 mM EDTA pH 8.0, 75 mM NaCl, 1 % SDS v/v, 7.8 % β -mercaptoethanol v/v, in DEPC treated water), and one volume of 25:24:1 phenol:chloroform:isoamyl alcohol (v/v) was added. After 13,000 rpm centrifugation at 4 °C for 10 min, the aqueous phase was transferred to a new tube and 1 volume of 24:1 chloroform:isoamyl
20 alcohol v/v added. After a second round of centrifugation, the upper phase was transferred to a fresh tube and LiCl added to a final concentration of 2 M. This solution was incubated for 1hr at -20 °C, and then centrifuged at 13,000 rpm at 4 °C for 15 min. The resulting pellet was re-suspended in DEPC treated water and the RNA was precipitated by addition of 0.1 volume of 3 M sodium acetate, pH 5.5 and
25 2.5 volumes of absolute ethanol followed by incubation for 20 min at 4 °C. This sample was then centrifuged at 13,000 rpm at 4 °C for 15 min and the resulting pellet was washed with 70 % ethanol, dried and re-suspended in DEPC treated water. Quantity and quality of the extract were estimated by measuring optical density at 260 and 280 nm (1 O.D._{260 nm} = 40 $\mu\text{g/ml}$ RNA). An aliquot of the extract was also
30 visualised on a 1 % (w/v) agarose gel containing ethidium bromide.

For the cDNA library construction, poly(A)⁺ RNA was prepared with the Poly(A) Quick® mRNA isolation kit (Stratagene) from cells harvested during the exponential phase.

5

cDNA library construction and pBluescript phagemid excision

Double-stranded, end-adapted cDNA synthesised using a cDNA synthesis kit (Stratagene) was passed through a Sepharose CL-2B gel filtration column (Stratagene) to remove adapters and small cDNA molecules. cDNA eluted from the
10 column was phenol-extracted, ethanol-precipitated and ligated to arms of the Uni-ZAP XR Vector (Stratagene) before packaging into λ phage using the Gigapack III Gold Packaging Extract (Stratagene). A primary library of 3×10^6 plaque forming units (pfu) was obtained with the majority of the inserts examined ranging from 0.3
15 to 1.5 kb. The library was subsequently amplified.

After amplification, the cDNA library was excised using the ExAssist™ Interference-Resistant Helper Phage (Stratagene). The excised phagemids were plated as individual bacterial colonies following the manufacturer's instructions. The presence
20 of insert was checked by PCR using universal primers and clones containing cDNA longer than 0.2 kb were selected for sequencing.

Sequencing and sequence analysis

Sequencing reactions were prepared with the ABI Prism Big Dye-Terminator cycle
25 sequencing kit (PE Applied Biosystems), using the universal T3 primer, and these were run on an ABI3700 (96-capillaries) sequencer (PE Applied Biosystems). The resulting Expressed Sequence Tags (ESTs) were processed such that all vector sequences were removed and further examined using standard nucleotide sequence alignment algorithms in order to identify EST clones with overlapping sequences.
30 These overlapping sequences were then assembled into contigs. These contigs were

annotated by comparison with the non-redundant peptide and nucleotide databases available from the National Centre for Biotechnology Information (NCBI). The NCBI databases had been downloaded to a local Silicon Graphics Server which allowed the annotation of thousands of ESTs to be performed as a batch job using the
5 BLAST 2 sequence alignment algorithm (Altschul *et al.*, 1997).

The *PIELO1*, *PIELO2*, *PIDES1*, *PIDES2*, *PLACSI* and *PIDGAT2-1* clones were identified on the basis of homology with other fatty acid elongase/desaturase/acyl-CoA synthase or diacylglycerol acyltransferase genes in the NCBI nucleotide and
10 protein databases.

Functional analysis of by heterologous expression.

Functional characterisation of the amino acid sequence encoded by *TpELO1.2*, 2.2 and 2.3 will be performed under protocols previously described (Jaworski *et al.*,
15 2001(or refer to as: US Patent No. 6,307,128);Qi *et al.*, 2002). To this aim, several species of fatty acid substrates will be considered: saturated (16:0, 18:0, 20:0, 22:0), monounsaturated (16:1, 18:1, 20:1) and polyunsaturated (20:4n-6, 20:5n-3, 22:5n-3).

Functional characterisation of the amino acid sequence encoded by *PIDES1* and
20 *PIDES2* will be performed under protocols previously described (Qiu *et al.*, 2001). To this aim, several species of fatty acid substrates will be considered: saturated (16:0, 18:0), monounsaturated (16:1, 18:1) and polyunsaturated (18:2n-6, 18:3n-3, 18:3n-6, 18:4n-3; 20:2n-6, 20:3n-3; 20:3n-6, 20:4n-3, 20:4n-6, 20:5n-3, 22:4n-6, 22:5n-3 and 22:5n-6).

25

Functional characterisation of the amino acid sequence encoded by *PLACSI* will be performed under protocols previously described (Kang *et al.*, 1997). To this aim, several species of fatty acid substrates will be considered: saturated (8:0, 10:0, 12:0, 16:0, 18:0, 20:0, 22:0), monounsaturated (14:1, 16:1, 18:1) and polyunsaturated
30 (18:2n-6, 18:3n-3, 18:3n-6, 20:4n-6, 20:5n-3 and 22:6n-3).

Functional characterisation of the amino acid sequence encoded by *PIDGAT2-1* will be performed under protocols previously described (Lardizabal *et al.*, 2001; Cases *et al.*, 2001, Zou *et al.*, 1999). To this aim, DGAT activity will be assayed by
5 incorporation of [$1\text{-}^{14}\text{C}$] diacylglycerol into TAG in the presence of several species of fatty acyl CoA substrates that are representative of fatty acids that partition to TAG in *P. huthari*. These include: 14:0, 16:0, 16:1, 18:0, 18:1, 18:2, 18:4, 20:5 and 22:6.

TAG extraction and fatty acids analysis

10 The alga cells (2 ml of culture medium) were harvested during the experimental period by centrifugation at 13,000 rpm for 15 min. Fifty μg of tripentadecanoin (15:0-TAG) were added to the pellet as an internal standard. The pellet was then suspended in 1 ml of 2:1 chloroform:methanol (v/v) and frozen in liquid nitrogen.
15 After 1 hour at 4°C , the cell debris was discarded by centrifugation and 0.3 ml of 0.9% KCl added to the supernatant. After centrifugation, the bottom phase was transferred into a 2 ml Ependorf and the KCl rinsed with 0.5 ml of chloroform. The chloroform phases were pooled and dried. The FA extract was suspended in 0.2 ml of hexane, and this volume was divided in 2 fractions of 0.1 ml. The first fraction
20 was dried, and the lipid extract suspended in 0.2 ml of hexane. This represented the total lipid extract. The second fraction was used to isolate the TAGs by hydrophobic chromatography. Bond Elut (Varian) 1 ml solid phase extraction columns with 100 mg Si packing were used to partition TAGs from other lipids in algal extracts. This protocol was adapted from a method described by Yongmanitchai and Ward (1992).
25 The eluate was dried and the TAG extract suspended in 0.2 ml of hexane. The products of these two extractions were analysed by GC as described previously by Larson and Graham (2001).

The same methodology will be employed to extract lipids and fatty acids from yeast
30 cells in order to perform the functional analysis of *TpELO 2.1*, *2.2* and *2.3* and *PIDES 1* following the feeding of different fatty acids as outlined above.

Cloning and characterization of the genes *PIELO1*, *PIELO2*, *PIDES 1*, *PIDES 2*, *PLACSI*, *PIDGAT2-1*, *TpELO2.1. 2.2* and *2.3*

5 The first pass sequencing of 5,719 cDNA clones from a cDNA library prepared from *P. lutheri* resulted in the identification of 34 cDNA clones from a single gene which gives a predicted amino acid sequence that has significant identity with fatty acid elongase genes from a variety of organisms. This abundance of copies of the elongase gene indicates that it is expressed at a significant level in *P. lutheri* cells
10 that are producing DHA.

The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the identification of four cDNA clones from a single gene which gives a predicted amino acid sequence that has significant identity with fatty acid desaturase genes from a
15 variety of organisms (Figure 3a and 3b). This desaturase gene has been designated *PIDES 1*.

The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the identification of three cDNA clones from a single gene which gives a predicted
20 amino acid sequence that has significant identity with fatty acid desaturase genes from a variety of organisms (Figure 4a and 4b). This desaturase gene has been designated *PIDES 2*.

The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the
25 identification of twelve cDNA clones from a single gene which gives a predicted amino acid sequence that has significant identity with acyl-CoA synthetase genes from a variety of organisms (Figure 5a and 5b). This acyl-CoA synthetase gene has been designated *PLACSI*.

30 The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the identification of one cDNA clone which gives a predicted amino acid sequence that

has significant identity with diacylglycerol acyltransferase 2 genes from several organisms (Figure 6a and 6b). This diacylglycerol acyltransferase 2 gene has been designated *PDGAT2-1*.

- 5 The full length cDNA and protein sequence of *PIELO1* and *PIELO2* is disclosed in Figures 7a, 7b, 7c and 7d respectively.

The *Tp ELO2.1*, *2.2* and *2.3* genes were identified by screening a *Thalassiostra spp* genomic database which can be found at <http://www.jgi.doe.gov/> with *PIELO 1* and
10 *PIELO 2*.

REFERENCES

15

1. Uauy R, Mena P, Rojas C Essential fatty acids in early life: structural and functional role. *Proc Nutr Soc* 2000 Feb;59(1):3-15
- 20 2. Dewailly E, Blanchet C, Lemieux S, Saurve L, Gingras S, Ayotte P, Holub BJ. n-3 Fatty acids and cardiovascular disease risk factors among the Inuit of Nunavik. *Am J Clin Nutr* 2001 Oct;74(4):464-73
3. Salem N *et al.* (1994) "Arachidonate and docosahexaenoate biosynthesis in various species and compartments in vivo." *World Review of Nutrition and Dietetics*, vol. 75, pp. 114-119.
25
4. Haag, M. Depressive Symptoms in Schizophrenia. *The Medicine Journal*, November 2001. Page 1-7.
- 30 5. Qi B, Beaudoin F, Fraser T, Stobart AK, Napier JA, Lazarus CM. Identification of a cDNA encoding a novel C18-Delta(9) polyunsaturated fatty acid-specific

elongating activity from the docosahexaenoic acid (DHA)-producing microalga, *Isochrysis galbana*. FEBS Lett 2002 Jan 16;510(3):159-65

- 5 6. Ashford A, Barclay WR, Weaver CA, Giddings TH, Zeller S. Electron microscopy may reveal structure of docosahexaenoic acid-rich oil within *Schizochytrium* sp. Lipids 2000 Dec;35(12):1377-86
- 10 7. Hammond BG, Mayhew DA, Robinson K, Mast RW, Sander WJ. Safety assessment of DHA-rich microalgae from *Schizochytrium* sp. Regul Toxicol Pharmacol 2001 Jun;33(3):356-62
- 15 8. Simonpolous AP. Essential fatty acids in health and chronic disease. Am. J. Clin. Nutr. 1999;70 (3); 560S-569S.
9. Horrocks LA & Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 1999;40(3):211-
- 20 10. Collos, Y., Mornet, P., Sciandra, A., Waser, N., Larson, A., Harrison, P.J., 1999. An optical method for the rapid measurement of micromolar levels of nitrate in marine phytoplankton cultures. Journal of Applied Phycology 11, 179-184.
- 25 11. Harrison, P.J., Waters, R.E., Taylor, F.J.R., 1980. A broad spectrum artificial seawater medium for coastal and open ocean phytoplankton. Journal of Phycology 16, 28-35.
12. Larson, T.R. , Graham LA., 2001. A novel technique for the sensitive quantification of acylCoA esters from plant tissues. The Plant Journal 25, 155-125.
- 30 13. Thompson, P.A., Harrison, P.J. , Parslow, J.S., 1991. Influence of irradiance on cell volume and carbon quota for ten species of marine phytoplankton. Journal of Phycology 27, 351-360.

14. Yongmanitchai, W., Ward, O.P., 1992. Separation of lipid classes from *Phaeodactylum tricornutum* using silica cartridges. *Phytochemistry* 31, 3405-340.
- 5 Broun P, Boddupalli S, Somerville C. 1998. A bifunctional oleate 12-hydroxylase: desaturase from *Lesquerella fendleri*. *Plant J* 13(2): 201-10
- Schnurr JA, Shockey J, Browze J. 2000 Characterization of an acyl-CoA synthetase from *Arabidopsis thaliana*. *Biochem Soc Trans*. Dec;28(6):957-8.
- 10 Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, Nagura H, Iijima H, Yamamoto TT. 1997 A novel arachidonate preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. *Proc Natl Acad Sci U S A*. Apr 1;94(7):2880-4.
- 15 Qiu X, Hong H, MacKenzie SL. 2001 Identification of a Delta 4 fatty acid desaturase from *Thraustochytrium* sp. involved in the biosynthesis of docosahexanoic acid by heterologous expression in *Saccharomyces cerevisiae* and *Brassica juncea*. *J Biol Chem*. Aug 24;276(34):31561-6.
- 20 Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusa AJ, Erickson SK, Farese RV Jr. 1998. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. *Proc Natl Acad Sci U S A*. Oct 27;95(22):13018-23.
- 25 Hobbs DH, Lu C, Hills MJ. 1999. Cloning of a cDNA encoding diacylglycerol acyltransferase from *Arabidopsis thaliana* and its functional expression. *FEBS Lett*. 11;452(3):145-9.
- Jako C, Kumar A, Wei Y, Zou J, Barton DL, Giblin EM, Covello PS, Taylor DC.
- 30 2001. Seed-specific over-expression of an *Arabidopsis* cDNA encoding a

diacylglycerol acyltransferase enhances seed oil content and seed weight. *Plant Physiol.* 126(2):861-74.

Lardizabal KD, Mai JT, Wagner NW, Wyrlok A, Voelker T, Hawkins DJ. 2001.

- 5 DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides from *Mortierella ramanniana* with diacylglycerol acyltransferase activity. *J Biol Chem.* 19;276(42):38862-9.

Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, Voelker T, Farese RV Jr.

- 10 2001. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. *J Biol Chem.* Oct 19;276(42):38870-6.

Zou J, Wei Y, Jako C, Kumar A, Selvaraj G, Taylor DC. 1999. The *Arabidopsis thaliana* TAG1 mutant has a mutation in a diacylglycerol acyltransferase gene. *Plant*

- 15 *J.* 19(6):645-53.

20

25

30

35

Claims

1. A transgenic cell comprising a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:
- 5
- i) a DNA molecule consisting of a DNA sequence as represented in Figures 1a, 1b or 1c;
 - ii) a DNA molecule which hybridises to the sequences identified in (i) above and which encode a polypeptide which has fatty acid elongase activity; and
 - 10 iii) DNA molecules consisting of DNA sequences that are degenerate as a result of the genetic code to the DNA sequence defined in (i) and (ii)
2. A cell according to Claim 1 wherein said nucleic acid molecule anneals under stringent hybridisation conditions to the sequences described in (i), (ii) and (iii) above.
- 15
3. A cell according to Claim 1 or 2 wherein said nucleic acid molecules are isolated from an algal species.
- 20
4. A cell according to Claim 3 wherein said algal species is selected from the group consisting of: *Amphidinium carterae*, *Amphiphora hyalina*, *Amphiphora sp.*, *Chaetoceros gracilis*, *Coscinodiscus sp.*, *Cryptocodinium cohnii*, *Cryptomonas sp.*, *Cylindrotheca fusiformis*, *Haslea ostrearia*, *Isochrysis galbana*, *Nannochloropsis oculata*, *Navicula sp.*, *Nitzschia closterium*, *Pavlova lutheri*, *Phaeodactylum tricornutum*, *Prorocentrum minimum*, *Rhizosolenia setigera*, *Skeletonema costatum*, *Skeletonema sp.*, *Tetraselmis tetrahele*, *Thalassiosira nitzschoides*, *Thalassiosira heterophormia*, *Thalassiosira pseudonana*, *Thalassiosira stellaris*.
- 25
- 30

5. A cell according to any of Claims 1-4 wherein said polypeptide is a variant polypeptide and comprises the amino acid sequence represented in Figure 2a, 2b, or 2c which sequence has been modified by deletion, addition or substitution of at least one amino acid residue wherein said modification enhances the enzyme activity of said polypeptide.
6. A cell according to Claim 5 wherein said modified polypeptide has enhanced fatty acid elongase activity
7. A cell according to any of Claims 1-4 wherein said polypeptide comprises the amino acid sequence represented in Figures 2a, 2b or 2c.
8. A cell according to Claim 7 wherein said polypeptide consists of the amino acid sequence represented in Figures 2a, 2b or 2c.
9. A cell according to any of Claims 1-8 wherein said cell is transfected with a nucleic acid molecules selected from the group consisting of nucleic acid sequences selected from the group consisting of:
- i) a DNA molecule consisting of the DNA sequence as represented in Figures 1a, 1b or 1c;
 - ii) DNA molecules which hybridise to the sequences identified in (i) above and which encode a polypeptide which has fatty acid elongase activity; and
 - iii) DNA molecules comprising DNA sequences that are degenerate as a result of the genetic code to the DNA sequence defined in (i) and (ii); combined with at least one of the nucleic acid molecules selected from the group consisting of:
 - iv) DNA molecules consisting of DNA sequences as represented in Figures 3a, 4a, 5a or 6a;

- v) DNA molecules which hybridise to the sequences identified in (i) above and which have desaturase, acyl-CoA synthetase or diacylglycerol acyltransferase activity;
- vi) DNA molecules comprising DNA sequences that are degenerate as a result of the genetic code to the DNA sequence defined in (iv) and (v) above.
10. A cell according to Claim 9 wherein said cell is a plant cell.
11. A plant comprising a cell according to any of Claims 1-10.
12. A seed comprising a cell according to any of Claims 1-10.
13. A foodstuff product comprising a cell according to any of Claims 1-10.
14. A foodstuff product according to Claim 13 wherein said foodstuff is selected from the group consisting of: wine; beer; bread, baking products (e.g. bread, cake); vegetable extracts.
15. A food stuff according to Claim 13 wherein said foodstuff is wine or beer.
16. A fermentation process comprising a cell according to any of Claims 1-10.
17. A fermentation process according to Claim 16 said process comprises the steps of:
- i) providing a vessel containing a cell according to the invention and constituents required for fermentation and fatty acid biosynthesis; and
- iii) providing conditions conducive to the fermentation of the liquid composition contained in said vessel.
18. An animal feed product comprising a cell according to any of Claims 1-10.

19. A method of modulating the level of n-3 fatty acid in a plant cell comprising;

- 5
- i) providing a plant cell according to Claim 10;
 - iv) regenerating the plant cell into a plant; and
 - v) monitoring n-3 fatty acid production by said plant.

20. A method for the production and optionally the extraction of n-3 fatty acids comprising:

- 10
- i) providing a cell according to any of Claims 1-10;
 - ii) providing conditions conducive to the growth of said cell; and
 - iii) extracting n-3 fatty acids, or variants thereof, from said cell.

21. A method for the production and optionally the extraction of n-3 fatty acid comprising:

- 15
- i) providing a plant cell according to Claim 10;
 - ii) regenerating said cell into a plant; and
 - iii) extracting n-3 fatty acids, or variants thereof from said plant.

20 22. A reaction vessel comprising at least one cell according to the invention, fatty acid substrates and co-factors characterised in that said vessel is adapted for the conversion of said fatty acids substrates to n-3 fatty acids.

25

30

Abstract .**Transgenic Cell**

- 5 We describe transgenic cells comprising nucleic acid molecules which comprise nucleic acid sequences which encode enzymes involved in the biosynthesis of n-3 fatty acids.

Figure 1a

Tpel2.1, genomic DNA sequence, complete ORF

NCNCGCAGCAGGGTGC CGCGCAAATTTTGAAGGAATTTTCGAGGGTGAAATTA
 GTGCGGCGACTAAATGTCGGATGACAATAAGATTAAACGGGATTTATCAAC
 GGGGAAAACACGGAAATATGTTCCCGTAGAGAAATAATGCTCTCGTTAAAT
 TTAGTTATAATCTTAAACAAATTTAGTGGTCAATATAATAGACAAAATGA
 CAAATGATGTGACTCTTTCCGCCACCACTCTTCAAGACCAACTGTTTTT
 TGTCCCTCTCTCTCTCAGTTGCTACGATTTCTGTGACCTCTCTTCTCTTA
 CTACCGTCTGGCTTCCAACACCATCATGTTCTGCAATTCCTAACCGCAATC
 CCAAGGAATGCGTAGGCACCAACGCTCTGGAGTCCCACTACCGCGAATC
 CTCTGCTCTCAACCTCTCCTCTCGCGCCACCTACCTCTCCCTTCGAACGCT
 TCTACGATCCCGTCCGCCACCTCACTCTGGATGCAAGATGCTCCCATGATC
 CCGATGATCGCGCTGCGTCCCTACGCTCTGCTCATCGTCTCTGGACGCGC
 CTACATAAGGACCGGCGCGCTGTGAGCTGGAGGAGGATTTTGGCCGTTT
 GGAATTTGAGCCTGTCTGCTCTTCTCTGATTTGGCGGATCAGGACGGCT
 CCTCAGTTGTATTACAACCTTGACGACGATTAATCTGTTGGGATTAATTTGTG
 CGATGATCCGGCGGCGTTTGTATGGGAGTGGATCGACGGGACTTTTGGGTGC
 AGTTGTTCAATTTGAGCAAGTTTCCCGAGTTGCTTGACACTTTCTTCATT
 GTCAATCACAAGAGCCGCTCATCTCTCTCCATTTGATATCATATAC
 COTCTTTCTTTACTGCTGGCAATCTCTATGACCACTTCTCCCACTGGGTC
 TCTTCTCTCTCTCATGAACTACAGTGTTCAGCGGGTCTATGTATGGGTAC
 TACTTCTCTCATGGCGGTCAAATTCCTGCCAAATGTTCAAACCCATGTT
 CGTGAAGTTCAATGCACTTTCTCAAATGTTTATTGGGGTGGGAGTTACCA
 TTGTGGCAATTTATTAATTACAGTAATCCGATTTTGGGAAAGACATGTCAT
 ATCAGGAAGGGAACAATGTTGCGGCTTTGTCTATGTACGGGAGCTACTTT
 TTAATGTTTGGCAAAATCTTTGTGGCGAGGTATTATAAGGTTAAGGTCA
 AGGGGGATCCGAAGAGAAGAAGAGTTGTGTAAAGTGAGAGATGGAATGA
 ACAACCATCTTGTTTGGGGAAGGGGGTATTGGATAGCGGTACCACTCAG
 TATCGTTGAGGTGCATTTAATGTTGAATGAACAACTTGACGAGACGAGG
 GATTTTGAATCTTCATGAACGAGTGGGAGCATCTTTCATTCATTGGGGAG
 AGAGGGAAGTGTAGAGAAGTGCTACTTTTGGGAGTTTGAGAGAGTTAAATTA
 ATGTCCTTTGTGTATGAATTCTGCTCTCAA AAAACGCAACGTGCTAGCAAAC
 CTCGTTAACAAATGACAAAGTTATTCTTGTGTATGGGACATACCAACGAT
 TGTATCATAAAAGAAAACCAATTCTATTGAGTTGTAAACATCTAGAGTGC
 AGTATCGAGCAACAGCCACGCCATCACGATACACTAAACACACATTTCGT
 CTTCACTTTACATTCTAACCAAGCATGCTGGCTCTCTTACCTCTTCAN
 NC

Figure 2a

Tpel02.1, cDNA sequence, complete ORF

AGCGGGGGTTCCTACGATTCCGTGACCTCCTTTCTCTACTACGCTGGCTCGAAGACCAT
CATCATCTCCGCAATTCTTAACCGCATCCCGAAGCAATGGGTAGGACCAACGGGCTCGG
AGTCGATGACCGCGAATTTCTCTGGCTCGACCTCTCTCTCGCGGACCATACCTCCCTCT
CGAACGCTTCTACGATCCGCTCGGCACCTTCACGTGATGCAAGATCGTCCCATATGCC
CATCATCGCTCTGCTCCCTGCTACGCTGCTGTCATCTGCTCTGGAGCGCGCTCATATGAGGA
CGCGCGCGGTGGAGCTGGAGGAGGATTTGGCGATTTTGGGAATTTGAGCGCTTCCGCTCT
GTGGTGGAATTGGCGCATACGAGCGGCTTCTCGATTGTATACAACTTGAAGCATTTTC
TTGGAGGATTAATTTGTGCGATGATCCGCGGGCGTTGTATGGAGTGGATCGACGGGACT
TTGGGTGCACTGTGCTATTTTGAAGCAAGTTCCCGAGTTCTGTGACATCCGCTGTGTTA
CAITTCACAGAGGCGCTCATCTTCTCCATCTCCGATTCATCATATCAAGCTGTGTTA
GTGCTGGCGCTCTATGTGACCAAGCTTCTCCAGTGGTCTCTCTTGTGTGCTCATGAACTA
CAGTGTCCACCGGCTCATGTATGGTACTACTTCTCCATGGCGGTCAAACTCCGTCGCA
ATGGTTCAACCCCATGTTCTGAGCTCTATGCAACPTTCAAAATTTTATGGGGTGGG
AGTTACCATTTGCGCATTTTATTATACATGATCCGATTTTGGGAAAGACATGTCATAT
CAGGAAGGAGAACATGTTTTCGCGCTTTTGTATGATACGGGAGCTACTTTTACTGTTCCG
ACATTTCTTTGTGCGGAGGATTTATAGGTTTAAAGTCAGCGGATCACTTTTACTGTTCCG
GTTTGTGTAAAGTGAAGATGGAATGAACAACCATCTTGTTTGGCCAGGGGGTATTGG
ATAGCGGGTACCACTCAGTATCGTTAGGTTGAGTATTAATTTGAATGAACAACTTGAAG
AGACGAGGCTTTTGAATCTTCATGAACGAGTGGGAGTCTTTCAATGCATTTGGGAGAG
AGGCAAGAGTGAAGAGAGTCTACTTTGGAGTTTGAAGAGTAATTTAAAGCTTTTTCG
AAAAAATAAATAAATAAATAAATAA

Figure 2a

TpELO2.1, amino acid sequence from genomic DNA, complete ORF

MSQFLTSIPKECVGTINGLGVHYAEFSCLHPLLQATYLPFERFYDPVATLTWMDRPMIPI
IACVAYVVLIVLGRAYMKORPANWSRRILAVWNLSLSLPSWIGAIRTAPQLYYNLTTYSL
RDNLCDDEPAALYSGSGSTGLWVQLFILSKFPPELLDTFFIVIHKKPLIFLEWYHHITVLLYC
WHSYVTTSPSGLFFVVMNYSVHAVMVGYYFLMAVIFRPKWFNPMFVTFMQLSQMFIGVGV
TIVAFYYYSNPILGKTCHIRKENNVAAAFVMYGSYFYLFAQFFVARYYKVKVKGDAAKKKKV
V

TpELO2.1, amino acid sequence from cDNA

MSQFLTSIPKECVGTINGLGVHYAEFSCLHPLLQATYLPFERFYDPVATLTWMDRPMIPI
IACVAYVVLIVLGRAYMKORPANWSRRILAVWNLSLSLPSWIGAIRTAPQLYYNLTTYSL
RDNLCDDEPAALYSGSGSTGLWVQLFILSKFPPELLDTFFIVIHKKPLIFLEWYHHITVLLYC
WHSYVTTSPSGLFFVVMNYSVHAVMVGYYFLMAVIFRPKWFNPMFVTFMQLSQMFIGVGV
TIVAFYYYSNPILGKTCHIRKENNVAAAFVMYGSYFYLFAQFFVARYYKVKVKGDAAKKKKV
V

Figure 1b

Tpelo2.2, genomic DNA sequence, complete ORF?

GTGGTCTCATGGCGTGGGTCCCTTGGTTCTCCTTCGOTGTGCTCCCTCT
 CTCCTTCTCGGCGGTGTGTGCGGTCTTCGTTTTCATTTGCTTCTTTTCC
 CATCAGGTTTCTAGACGTGCGGGCCGCGTCTCTCTTGGGTTGGGCT
 TGCCCGCTTTGGTTTGATATCACAAAGTTACCTGGCAACCATGGACGCT
 TACAACCGCTGCAATGGATAAGATCGGTGCCGCCATCATCGATTGGTCTGA
 TCCGATGGCAAGTTCCGTGCCGATAGAGAGGTGAGCATGAATGTACACA
 CCATGGTTGTCTCGGCATGACGGTGTTCATTGGATGGTGTCAGTGCATCTC
 TCTGTTTGTCATCTATTCTAAACAACACATCTTTTACCTCGTTACCTTAC
 TCAACAACCTACCACACAACCATCATCATCTAGGACTGGTGGCTCTGCCA
 CTTCCGTAGCGCCATCACCATCGCTCTCTATCTACATCGCCTTCGTCTATCC
 TCGGTTCCGCGGTCAATCAATCCCTCCCGCAATGGATCCCTACCCCATC
 AAATTCTCTCAACCGTCTCCCAAATCTTCTTTGTGCTTACATGACTGT
 CGAGGCGGGATTTTTGGCCTACCGCAATGGATATACCGTCAATGCTTCCA
 ATCATTTCATATGTGAATGATCTCTCCCGTGGCGAATCTTCTTTGGTTGTTT
 TATATTTCCAAAGTGTGGGACTTTTGGGATACCATTTTCATTGTGTGGG
 GAAGAAGTGGCGTCAATTATCTTTCTTGTCATGTATACCATCACACCACCA
 TCTTCTATTCTATTGGCTGAATGCCAATGTCTTTACGATGGTGACATC
 TTCCTTACCATCTTGCTCAATGGATTTCATCCACAGGTGATGTACACGTA
 TTACTTTCATCTGTATGCTATACCAAGATCCCAAGACGGGCAAGAGTCTTC
 CTATATGGTGGAAATCGAGTTTGACGGCGTTTCAGTTGTTGCAATTCACT
 ATCATGATGAGTCAAGCTACCTACCTTGTCTTCCACGGGTGTGATAAGGT
 GTCGCTTCGTATCAGGATTGTGTACTTTGTGTACATTTTGAATTTGTCT
 TCTTTTGTGCTCAGTTCTTTGTGCAATCATACATGGCACCCAAAAAGAAAG
 AAGAGTGCTTAGATTGGAAAGCGGTGTGGCGGACGAGCTTTCCTGTTGAG
 GGTGGGTGGTGGAAAGGAGTTGCTTTTGTGAAGCATCTCAATATTGCGCA
 GGACTGTGTCTGTGAGAATAGCTATGGAGTAAAGGTGGGGGGGGGTGGAT
 TCATGGCGGACAGGCATGCCCTAAGATACTAAGGAATGTTTCATGAACATGA
 TGTGATACCTTATTGTAAAGGTACTGTGGGAATTAATGAGAGCGTACTG
 AAAGGAGAGATGAGTGTCTGTCAAACGCTTGGGTTAGTTGTTACTTTCC
 GTTCGTTCTTTTCACTATAGTCTTTGCTGAGGAGTTAATCCTAAGCTGA
 CACCATACGTTGAACAACGCAACCAATTAGCGTTGAGCCCGACAACCTCTC
 GACAAAGAGGTTTGTAGATTGTATCCCCTGGCGCAAGTTAACGTACAGG
 TGCTTCATTACGGAACCATATCCCATGGATGCATCTGTGCCAATAAC
 CTTCAAAAACGTTGCTCCCACTTGAGAAACCACTATTACGAGTTTCACC
 TCAGGTCTGACCGGCAAAAACAATTGAATCAGCAGCAAGGCCACAAGC
 AAGCACTTCGCGATGAGGACCAAGGAAGAGACGCTCACACCTCCCCGCC
 TTCGAGACGAGCCCCACGAGCGCGGTGG

Figure 2b

TPELO2.2, amino acid sequence from genomic DNA

DWHLCDFRSAITIALIYIAFVILGSAVMQSLPAMDPIYPIKFLYNVSIPLCAVMTVEAGF
 LAYRNGYTVMPCNHFNVMPPFVANLLWLFYISKVWDFWDTLFIVLGKQWRQLSFLHVVHE
 TTIFLFYWLNAVLYDGDIFLTILLNGFIHTVMYTYFFICMHTKDEPKTGKSLPIWVKSEL
 TAFQLLQFTIMMSQATYLVFEGCDKVSRLRITIVYFVYILSLFFLEAQFFVQSYMAPKRRK
 SA

Figure 10

Tpelo2.3, genomic DNA sequence (intron) :

AAAAAAAAAAAAAAAAAAAAAAGAGAGGAAATGTCGCACAACCGGCAGCTGCAGCTTCATG
 CCTGCAGGTCGACTCTAGAAGATCCCGGTGTTGTCAGTGTGGCGCAAGTGTCTGCTCAAA
 GGGTGGACGGTGTATGCGAATTGTGGATGCGGTGATGAATAGAGACCATCCATTATTGGA
 AGTAGAAGTTTGGTTGGGGCGGCGTTGCATAGTGGGAGCTCGTATGCGGTGTGGGTTTAT
 TATTGTGATAAGTATTTGGAGTTCTTTGATACGTATTTTATGGTGTGAGGGGGAAAAATG
 GACCAGGTGCAATTGACGAGTTGCTGTGTTAGTGTGGTTAGATGGTACTTGGTGAAGTTGG
 TGACAGTGTGTGGTGTGGCGTTGGATATATGATATGAGAGAAGGTACCAATGTGTTGGAA
 GGAACAATGAGACACATCTCGCGCAGATGTCAGAGAGACCAATCTGCAACGATTCAAA
 GATCATTTAAGAGTTCATCAGCTACGCAGAGAATGGTGTAATGATCAGTGTTCAGTTTC
 AAAAGTTGGCATGATACTACTCAGCTTTGAAGTGCATCGGTCTGCTACGGGAACGGGAA
 GGCTTTCACCAACAACGTTACCAATCCACATCTCACGCTTCCACCTCATTCTACAAAAC
 AAAAAAACAGGTCTCCTTCTCCACATCTACCACCACACGACCATAGCGTGGGCATGGTG
 GATCCCGCTCCGCTTCTCCCCCGGCGGAGACATTTACTTGGGGGCACTCCTCAACTCCAT
 CATCCACGTCCTCATGTATTCTCTACTACGCCCTTGCCCTACTCAAGGTCAGTTGTCCATG
 GAAACGATACTTGACTCAAGCTCAATTATTGTCAAATCACAAGTGTGGTGGTTTATACGGG
 GTGTACGGGTATACTCATTACTATCATACGAAGCATGAGCGGATGAGACACAGCCTAG
 TTTAGGAACGTATTATTTCGTTGTGGAGTGCAGGTGTGTTGAGATGGTTAGTTTGTGTTG
 ACTCTTTTCCATCTTTTATAAACGATCCTATTGGAAGAAACAGTCAAGGAGGAAGGA
 TAGCAAGAGAATGATGATGGAATAATGAGGATCAATGTCACAAGGCTATGAAGGATAT
 ATCGGAGGTCGCAAGCGAGGTGTTGGGGCATGCAGCGAAGGATGCTGGAAAGTTGGTGGC
 TACGGCGAGTAAGCGCTGTAAGAGGAAGGGAATCTGTGTTACTGGTCCATGTAGATAAA
 GAGGTTGAAGACAGATGAAGGCAACTCTTCATGATGGTGGTGGAAAGTTTCATCAACATTA
 ACTGTATGAATCAAGATAAAGGTGGTTGGACAAGGATGCTTGGAAATCGGCATGAATAG
 GAGAACAAGTTGCTAATGATTCTAGAGAATGTACATTCAAGCTTCTGTGATAAAGACGAT
 ACTCGGGATCGTCAAGTACCGTTTCGAAGTAGGCCATGCTCAAGACCGTGATATACTGA
 GTGCGCGGATCTATCTACTTGAAGCCATCCTTACTGTGCGGCGATCGAACAGAATTCCC
 GACGGG

Figure 2a

TpELO2.3, amino acid sequence from genomic DNA

MWRKCCSNQWTVYAIVDAVMNRDHPFFIGSRSLVGAALHSGSSYAVVWHYCDKYLEPFDITY
MVLRGKMDQVSFLHIYBETTLANAMWIALRFSFGGD.IYFGALLNSI IHVIMSYFALALL
VSCPWKRYLTAQALLQFTSVVVYTGCTGYTHYXTHKGADEITQPELOTYYFCGGVQVPFEMV
SLFVLPSIFYKRSYKKNKSGCKDSDKNDGANNEDQCHKAMKDISEGAKEVVGHAANKDAGK
LVATASKAVIKRSGTSTVTOAM

Figure 3b

— Deduced amino acid sequence of the *PIDES1* coding sequence.

```

MPFAAABSG VASLRAABVA STERJAVDER FDLITVGDAY YDAKAFDER FVGAHVSLE
GGRDATEAFM KYHRAATWPCA AMSKFFVGSIL DASSEPTQAD SAKLRLCAEV NALLPKGSGG
TAPPSYWLKA AALVVAAVSI SGTHLLRGKT LALVELGLV FANDQINIQH DAMEGALSRH
SVNTICIGYA GDNIGGEMVL WLQEHVVMKH LHTSDVDADP DQKAGVIAL KPTDGMHNE
ALQQLYILPG EAMYAFKLLP LDALHLLAWR WSGEKLSPLA RALFAPAVAC ELGFWARFVA
LPLNLQPTVK TALCICATVO TGSFYLAFFP FISHNFDGVS SVQFEGSLPR SATFVQHQVE
TRENVOOTNL GVINGCLMFO IERHLPDRIM NSTKAGIAPV VRHIEKLAG KCHFFPTVGS
NLSKGLQHGK SGSTRPAKK GKCAE

```

Figure 4a: Nucleotide sequence of *PIDBS2*. Two potential stop codons are highlighted.

GCACGAGGGTGTCTGTACTCTGCTGTACGCTCTCCCTCGGCTCGATGTACAT
CTTCTGCAACTTTGCCGTGTCTGCACACGCGATCTGCGCATCGTTGAGGCGG
ACCAGCACGCCACCTGGGTTGAGTACTCGGCGCAACCAACGACCAACTGC
GCGCCCTCGTGTGTGTGCGACTGGTGGATGTCTTAAOCTCAACTACCAGAT
CGAGCATCATCTGTTCGCCGTGCATGCCGCGATTCGCGCACCCGACGATCG
GCGCGCGCTCTCAAGGCGCTCTCTCGCGAAGCGACGCGCTGCCTCTTGAAGTG
CGCGGCTACTTCTGAGGCGGATGCCGACATCGTTCTATGACCTTGACAAAGT
CGGCAACGCGCACGAGGCAAACTATTAGCGCGGTATGCGCTTGGAAAGAGG
CCTCCTGCATAAGCGGCGGACGCGCTCGGCGCGCGCGCGCGCTGCACGGGAGC
ACAAAGTGATGGATGGACCTTGGGCGGACGCGCGACGCGCAAGGAATGGTTG
TCTCTGTCTGTGGCCAGGCGCCAGGAGCCCAAGGGGACAGGGTTGCAGAGCTT
GGGCGCGATCTGAGGCGAGGCGCGCGCGCGCTCGGCGGCTTCCGAGTCTTGGCG
AGGCGCTCTGCGAGCTCTGCACGACTCGCGCGCGGACAGGCGGTGCGCGCGCGC
GCGAGTTCACAAAAA

Figure 4b: Deduced amino acid sequences of the *PUD32* coding sequence. The first stop codon was considered for the translation.

A R G C O Y L L Y V S L O S M Y I F C N F A V S H T H L P I V R A D Q H A T W Y
 B Y S A N H T T N C A P S W W C D W W M S Y L N Y Q I E S H L F P S M P Q F R E
 F T I A F R V K A L P E K H G L E Y D V R G Y F E A M A D T F M N L D K V G N A
 H E H N H

5a

Figure 5a: Nucleotide sequence of *PLACS1*. Three potential stop codons are highlighted.

GCACGAGGCTCTTCCGCTGGGCGCTCGACGACGCGCTCGCCAGTATGA
 CAAGGGCGGCGCTCGGCCCCGCTTCTCTGTAACAGCGCGTCTCTTCTCGT
 CGGTGCAAGGCGCTCTCGGCGGTGCGGTGCGCATGATGCTCGGCGGCTCC
 GCGCCCCCTCTCGGCGGACGTGCAAGAGTTTGTGCAATCGTCTTCAACGC
 GCGGCTTCCGCAAGGCTACGCGCTTACCGAGACGTGCGCGGCGGAGACGC
 TCTGCGCGCTGACGACAAACACGCGTCCGCAAGTTGGGCGGCGGCAAGAG
 TCGGCGTCTCTACGCTGCGGAGTGGGAGGAGGCGGAGCTACCGCAACCG
 CGACGCGCAACGACCGCGCGATCGGGATGCGGCGGCGGAGATCCTGATCG
 GTGGGCGGCGGCTCTGCGCTCTACTACGTGAACGAGCGGCGGCGGCGAC
 GCGGAGCTGTGTGAAGCGCAACGCGGAGGACTTTGTGACGATCAACGCGAT
 GCGCTTCTTCTGCTCGGCGGACATCGGCGGAGTACGCGGAGCGGCTGCG
 TGCAGATTATCGACCGGAAGAGGAGCTCTCAAGCTGCGGAGCGGCGAG
 TACGTGCGGCTCTCCAGGCTGAGAGACGCGCTCAGAACTGTCGTACAC
 GCAGATCCCGTACGTCTACGCGCTCTCTTCCAGAGCTTACTGATCGGCG
 TCTCTGCGCGGCGGCGGCGGCGATCCGCGGCGCTCGCGCGCTCGCTCGAG
 ATCAGCGGCGAGGAGCTTCCGAGCTGTGCGCGCACCGCGAGATCGTCCG
 GCGCGTCTCAAGGAGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG
 GCTTCAAGAGCGGCGGAGGAGCTCATCTCTGCTGTCGAGAGTGGAGCGTT
 GAGATGACATGCTTACCAAGAGATGAAGATCAAGCGCAAGCCAACTGCG
 TGACCGGCAAGCGGAGGAGATCAAGGCGGCTTACGCTCTGAGCGGCGGCGT
 TTTTGTACAACTCGAGAGCGGCGGCTCTCTGATGCGGCGGCGGCTGCTGT
 TGTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG
 AGCGCGGCGGAGGAGTGTCTGCGGAGTGGCGGCTGCGGCGGCTGAGCGG
 AAGGCGGCTCTCGGCTCTGAGAGGTTGGCGGCGGCTTGTGAGAGTGTTCG
 CAGCGGCTCTCGGCTCTGAGAGGTTGGCGGCGGCTTGTGAGAGTGTTCG
 TGCTGCGCTCTCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG
 TCACGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG

5b

Figure 5b: Deduced amino acid sequence of the *PLACS1* coding sequence. The first stop codon was considered for the end of the translation.

ARGLFQWALDDALAKYDKGGVGPGLYNNAVVFSSVQALLG
 GRVRMMVAGSAPLSADVQKFVQSCFNAPLRQGYGLTETCA
 ATTLCALHDNTFSQVGPQESACITLRDNWEGNYRNARDAN
 DPAIGMRRGHILIGGPAVCLGYVNERAPDADVVKRNARD
 FVTINCMRFFCSGDIGQITFSGCVQIIDRKKDVLVQLQQR
 YVALSKVENNALKNSSYTQIPYVYALSSKSYCIALLCPQEA
 AIRQLAASLQKSGKELSHLCANPQIVAAVLKDLQAQCKAA
 KLAGFBTPSKLXLVSDENWTVENPMLTTTMELEKRPIDRE
 ASEIFAVYV

Figure 6a

ACTGCGTGATACAGCATGGCGGCTCGCGCGGTTGACGCGCTCGTCGTGAGCGCGTTTCAC
GGCGTTTCGTGACATCGGCGTGTTGGCGCTCACGCCCGTGGGCATTGCGTGGGCGCTCGC
GTTCCACTGGAAGGTGACGCTGCCGCTGCTCGCCCTTTATCTCGCGTCGTACCTCGACGG
CGCCGAGGTGCGCGTCAAGCGCGTGC CGCGTGGCGCGCGTTCTCCGGGCATTTTGGCT
GTTACGTTTCATCGCGAGGGTCTACCGCGAGCGCGTTTCACGTGCCAGCTGGCCTCGAGGC
CGAGGAGCAGATCATCTAGCGCTGCATCCGACGCGCTCGATGGCGGACTACCGCGCGAT
GCTCGACGGCGGAGCTGCTCGACCTACTGCCCGCGCTGCGCGCAAGATGCGCTGGCTCGC
GGCGAGCGTGCTCTTTGGGCTTCCCATCGTGCGCGAGCTCACCCCTTTGGACCGGCTGCAT
CGACGCGCGCGCTCGGTTGCCGAGAGTGCGCTGCGTGGCGGCTACTCAGTCGGCGTACT
GCCGCGCGCGAGCAGGAGCAGCTGCGCACGCGGTACGGCGCGAGTCGGTATATTTCG
CAAGCGCTTTGGCTTCGTCAAGCTTGCGCTCCGCTTCGGCGTGCGGCTCGTGCGCTGGTA
CGTGTTGGGTTGCGTCGACCTGTACACAGTTCAATCCCTGCTCTTCTCGGCGCGCGAGTG
GCTCGTGCGCTCTCTCGGCGTGTCGTGCCGTTGCTTCGGAGCGTGGGGCGTGCCCAT
GGCGCGCTTGCTGTGCCGCTCAACGTCGTGATCGGCGCGCGGATCAAGCTGCCGCGCA
CGCTGAGCCGACCGATGAGGACCTCGCGCGCGCGCTCGACCGAGTACATCGCGCGCTGCG
CGGCTCTTTGACGAGAACAAAGCGCGCTTTGGCTATGCGGACCGCGAGCTGGAGGTGTG
CTGATTGTGAAGAGTGTCAATTGAAGGTGCGCGTCAACAGCGCACCGCGCACCAAGCCA
CTCAGCTCTTGATCGCTGAACCGCGCGTGAACGATGCGGTTGCGACACGCTTGAAGATGGC
CAGAAAAAAAAAAAAA

Figure 6b

MAARAVDALV VSAPTAFVQI GVNALTFVGI ANALAFHNKV TLFILALYLA SYLDQAEVRV
KRVANPAFS RHPWLFTHR KVRQRVHVP AGLEABEQIT LALHPHGSMA DYPAILDQQL
LDLLPALRCK MRWLAASVLF RLPFVREKTL WTGCIDARRS VAESALRGQY SVQVLPQGEQ
EQLRTHYGRS SVYLRKRFGF VKLALRFGVP LVPGYVFGCV DLYHTSEILF SAREWLVRSL
GVCVPVCJGA WGVYMAPLAV FLEVVIGRPI KLPRNPBPTD EDVARALDQY LAALRALFDS
NKAHFGYADB ELEVC

Figure 7a

GGCAGAGGGGAGAGATGCGCGCGGACATCGCCGTACGTCGCTGAATCGCGCGCGCGCGGCTACGCGTAC
CCGGAGCGGTGCAAAATGTCAGAGATGTCGAGAGCGCTGTCGCTACTCGAGAGGGCGGTGCACCCGCTCGTTAT
TCACAGCTCCGCGAGATCCTCGCGCGCGCGCTGCTGCTGTCATCGCGCGCGCTCAACCACTTTCCCAAGATACCG
TCGCGAGCTCTCGCCAGATCTGCGCTCGCTGTCAGATCGAGCTGGCGTACGCTTCGCGCTGACTGCGGTG
GCCGTGCTGCTCTCTCGCTACTACGCTCTCGCTCAACCGCGCGCTTACTCTCGTCTGCTGCGGACGTG
GCAGCTGCGCGAGACGACTAGGACGAGCGGAGCGCTGAGTGGAGAGGCGGATTTCTTCGCTCGAGCGATCAGG
ATTGCGGCAATTTTTGCGAGAGTGGGTGAGCTTCCAGATGAAGCTTTTGAAGCGCAACCAGATCTCCGAG
CGCTGCTACTTCCCACTTGGCATCGCGCGCTACCGGAGAGGGCGAGCGCGACTTTGACTTTTCGATGGCGCG
CGCGCGCAAGGAGTTCGAGACTGTGCTCTTCACGAGCGGTGAGAGCGCTGCTCGCCAAAGCAGCGGCGTAAAGC
CGCGGATATCGACATGCTGCTCGTCAACTGCTGCTCTTCAACCGGAGCGGATCGTGGCTGCGATCGTG
ATCAACCACTACCAAGTGAAGGACTCCGTCAGAGGCTACTCACTTGGCGGAGTGGGTGCTCAGCGGAGCT
CATCTCAATCCACCTCGCAAGGAGCTGCTGCGAGTCTACCCGCGCAAGCGCGCGCTCTGTCATCTCGAGCG
AGAACATCAGCGAAATTTTACAGGGCAACGAAAGTGGATGCTCATCTCGAACACCGCTCTTCGGAATG
GGCGCGCGCGCGCTCTCTCTTCGCGCGCGCGCTCGCGCGCGCGCGCTCGCCAAAGTCAACTGTCTGCAC
CGTCCGCGCGCGCAAGAGCGCGCGCGCGCGCGCTACCGTCTGCTCTTCGAGCGGAGGACAAGGCGGGGC
ACGTGGGCGTTCGCGCTTCGAAAGACGTGATGAGTTCGCGCGCGCGCGCGAGTGAAGACCAACATCTCGGTC
CTCGCGCGCTCTGATTTCTGCGCGCTTCTGAGCAGGTCCGATTTCTCGCAACTACGTTTCGCGCGAGTGGCT
GCGAATGAAGGCGTGAAGGGAATAGCTGCGCGGACTTCAACAGCGCGCTGCGACTCTTTTGCAATCCACAGCG
CGGGCGCGCGCTCGAGCGGCTGCGAGCGCTTTCGCTGCTGCGATTACTACTCTCGAGCGGAGCGGT
TACTCCTGTCGCGCTGCGGTAAAGCTCTCAAGCGCTCACTTCTGCTAGAGCTCGACTGGCTCGAAAGTTC
CGGCGCGCATCCGCGCGCGCGAGAGGTGTGGCAGATTGGGTTTGGCAGCGGCTTCAAGTGCAACTCGGCG
TCTGCGCGCGCGTTCGAGCGGATGCCGTAGCTACGCGCGCGCGCTCCGCAATTGCGAGTGGTTCTGTCAGAG
AGTCACTACTGACGAGTGCAGGTGACGCTGACGCGCTTCCCCCCCCCGCCACCACCTTCACCTCCACCTC
CTTCACTCTCACTCAATCGCGCGCGCGCGGACAGAGCGAGCGCTCGTCTCGCATCACCGCTTGTAGT
CTTCGCGCGCGCTCGAGCGGAGCGCGGCTCCATGAGCGGACAGCGAGCGAGAGAGAGCCACATCACA
GCAGAAAAAAGAAAAAAGAAAAAAGTGGAGACTAGTTCTCTCTACCGCGCTGCGAGCTCAAGCAGCGCGCG
GTGTCAGTCTCGCGCTCACCGGCTGCTTGTCCAGAGGTGTACTGTTGCGCGCGACCCGAGCGCGCTCT
CAGGCGCGCGAGCGCGCTCGCGCGCTCTCGACCGTGCAGCGCTCTCGCGCTCATCCAGCTCATGCTCTTC
TAGGCATCATCGAGGTGCGCTCGCGCAACTACAGGGCGCGCTGCCCGCGCAACTTGGCTTTGACCGGCTC
GG

Figure 7b

MAAPTSPYGA	ESFRAAYAYP	ERANVTOMSA	LRVLDEGVHP	LVIHSSQILA	AALLVTAAVN
EPFKITVADL	ABIWRSLQID	VAYAFALTAV	AVLLLGYYAL	RHPRFVYLVD	FATWQLRDDK
DDGSLGATED	PFRSTITDCG	NPCDESVDFQ	NKLFERNQIS	ERCYFPPGIR	AYRQGRDFFD
FSMAAARKCF	ETVVFTTVDE	LLAKTGVKGR	DIDILVNCB	LFNFTPLAA	IVINHYOMKO
SVQSYSLGGM	GCSAGLISIH	LAKDLLQVYP	RKRALVISTE	NITQNFYQGN	EKSMLISNTL
FRMGGAUVLL	SGRHADRRVA	KYQLLHTVRT	HKGADPDAYR	CVFQHEDEKAG	HVGVRLSKDV
MECAGRAMKT	NISVLAPLIL	FVSEQVRFLA	NYVARKWLRN	KGVKGYVDF	TTAVQHFCH
TGGRAVLDAL	QANLSLSYY	LEPSRYSLNR	WGNVSSASVW	YELDWLEKSG	RIRRGDKVWQ
IGFGSGFKCN	SAVWRACRAM	P			

Figure 7c

GCACGAGGCCCTCGTGCCGAATTCCGGCACGAGGCCGCGCTGTGCTCGTGGT
TACCGACGTACGACGAGTTTGTGATGGGCTTTGCTTCGTGACCGCGAG
AAGATCGGCGTGACATGGTGGACCAAGGCGGTGATTACCTCTGCGGAGTG
GGCGGCCATCTCGGTGACAAAGCACATGTCCTTCTTCTCCGACGCGGCCG
AGTTCACGGGCGACCACTGGATCATCCCGCTCGTGGGGTGGCACTCTAC
CTCGTGATGATCGTCTGGGCCCAATGATCATGGCCAAACCGGCCCGCT
CCCCGTGAATGGGCTCGCCTGCGGTTGGAACTGGTTCTGGGCCGATTCA
GCACTTTGCGGCGTGGCTTGACGTTGGCACTGTATCTTCACCAAGGCTGCGT
AGCCGCGGCTTCGAGAGCACGACGTGCGGCAGCGCCATGTTTCAATGTCGA
GGGGTACGTTGGCTTGCAATGCTGCTCTTCATCTACTCCAAGCTCTTCG
AGTTGATCGACACCTTCTTCTCATCGCGAAGAAGGCGGATGTGATCTTC
CTGATTTGGTACCACCGTCAACGCTGCTGCTCTACTGCTGGCACTCGCA
CTCGGTCCGGATACCGAGCGGGATCTGGTTCCGCGCGGATGAACCTTTG
TGACGCGCATCATGTACTCTTCTTTCGATGACGCGAGATGGGTCCGCGC
TACCGCAAGCTCGTCCGGCGGTACGCGCGGCTGATTACGACCTGCGAGT
CTCGCAGATGTTTCTCGGCCCTCATCGTCAACGGCTCGATCATTTACTTCA
CGTGGCTCGGGCACGCATGCAAGTTCGAGCAAGACGAACACGATCCTGAGC
TGGCTGATGTACCTCAGCTACTTTGTGCTATTCCGACTGCTCTACCTGCG
CAATTACATCCTTTGTTACACATGGCAAGCCGGCGGGCAAGCGCGCAAGG
GCAAGGCGGAATAGTGCAGGGGCGGGGAGGCGGTGCCACCCCGCGCTCG
CAAAGCGGTGCGGCTCCTTGCCCGAGATGCGACGAGAGTCCGAGAGGTGAA
ACCTCCTTAAATAATGCTACTCCTAGATTTTGGCTTTGTGCTTCGTTAT
AGATGCTCAGCC

Figure 7d

H E A S C R I R H E A A L W S W L P T Y D E F V D G L S F V D R E K I G V H M V
D Q G V I T S A E W A A I S V D K H M S F F S D A A E F T G D H W I I P L V A V
A L Y L V M I V V G P M I M A N R P P L P V N G L A C A W N W F L A A F S T F G
V A C T W H C I P T R L R S R G F E S T T C G S A M F M S Q G Y V G L A M L L F
I Y S K L F E L I D T F F L I A K R A D V I F L R W Y H H V T V L L Y C W H S H
S V R I P S G I W F A A M N Y F V H A I M Y S Y F A M T Q M G P R Y R K L V R P
Y A R L I T T L Q I S Q M P V G L I V N G S I I Y F T S L G H A C K S S K T N T
I L S W L M Y L S Y F V L P G L L Y L R N Y I L G T H G K P A G K R A K G K A E

PCT/GB2004/003057



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.